158 related articles for article (PubMed ID: 2310684)
1. Tumour-associated trypsin inhibitor (TATI) and cancer antigen 125 (CA 125) in mucinous ovarian tumours.
Mogensen O; Mogensen B; Jakobsen A
Br J Cancer; 1990 Feb; 61(2):327-9. PubMed ID: 2310684
[TBL] [Abstract][Full Text] [Related]
2. Tumor-associated trypsin inhibitor and cancer antigen 125 in pelvic masses.
Mogensen O; Mogensen B; Jakobsen A
Gynecol Oncol; 1990 Aug; 38(2):170-4. PubMed ID: 2167279
[TBL] [Abstract][Full Text] [Related]
3. Tumour-associated trypsin inhibitor (TATI) in ovarian cancer.
Halila H; Lehtovirta P; Stenman UH
Br J Cancer; 1988 Mar; 57(3):304-7. PubMed ID: 3162682
[TBL] [Abstract][Full Text] [Related]
4. Cancer-associated antigen CA 195 in patients with mucinous ovarian tumours: a comparative analysis with CEA, TATI and CA 125 in serum specimens and cyst fluids.
de Bruijn HW; ten Hoor KA; Boonstra H; Marrink J; Krans M; Aalders JG
Tumour Biol; 1993; 14(2):105-15. PubMed ID: 8392219
[TBL] [Abstract][Full Text] [Related]
5. Tumor-associated trypsin inhibitor (TATI) and cancer antigen 125 (CA125) in patients with epithelial ovarian cancer.
Peters-Engl C; Medl M; Ogris E; Leodolter S
Anticancer Res; 1995; 15(6B):2727-30. PubMed ID: 8669854
[TBL] [Abstract][Full Text] [Related]
6. TATI (tumour-associated trypsin inhibitor) as a marker of ovarian cancer.
Medl M; Ogris E; Peters-Engl C; Leodolter S
Br J Cancer; 1995 May; 71(5):1051-4. PubMed ID: 7734298
[TBL] [Abstract][Full Text] [Related]
7. Tumour-associated trypsin inhibitor (TATI) in human ovarian cyst fluid. Comparison with CA 125 and CEA.
Halila H; Huhtala ML; Haglund C; Nordling S; Stenman UH
Br J Cancer; 1987 Aug; 56(2):153-6. PubMed ID: 3117086
[TBL] [Abstract][Full Text] [Related]
8. Tumour-associated trypsin inhibitor in the diagnosis of pancreatic carcinoma.
Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttilä I; Alhava E
J Cancer Res Clin Oncol; 1994; 120(8):494-7. PubMed ID: 8207049
[TBL] [Abstract][Full Text] [Related]
9. Comparison of tumor-associated trypsin inhibitor (TATI) with CA125 as a marker for diagnosis and monitoring of epithelial ovarian cancer.
Gadducci A; Ferdeghini M; Rispoli G; Prontera C; Bianchi R; Fioretti P
Scand J Clin Lab Invest Suppl; 1991; 207():19-24. PubMed ID: 1780685
[TBL] [Abstract][Full Text] [Related]
10. Tumour-associated trypsin inhibitor (TATI) in patients with colorectal cancer: a comparison with CEA, CA 50 and CA 242.
Pasanen P; Eskelinen M; Kulju A; Penttilä I; Janatuinen E; Alhava E
Scand J Clin Lab Invest; 1995 Apr; 55(2):119-24. PubMed ID: 7667604
[TBL] [Abstract][Full Text] [Related]
11. Claudin-5 is associated with elevated TATI and CA125 levels in mucinous ovarian borderline tumors.
Nissi R; Talvensaari-Mattila A; Kuvaja P; Pääkkö P; Soini Y; Santala M
Anticancer Res; 2015 Feb; 35(2):973-6. PubMed ID: 25667483
[TBL] [Abstract][Full Text] [Related]
12. Tumour-associated trypsin inhibitor (TATI): comparison with CA125 as a preoperative prognostic indicator in advanced ovarian cancer.
Venesmaa P; Lehtovirta P; Stenman UH; Leminen A; Forss M; Ylikorkala O
Br J Cancer; 1994 Dec; 70(6):1188-90. PubMed ID: 7981075
[TBL] [Abstract][Full Text] [Related]
13. Serum CA19.9 levels are commonly elevated in primary ovarian mucinous tumours but cannot be used to predict the histological subtype.
Kelly PJ; Archbold P; Price JH; Cardwell C; McCluggage WG
J Clin Pathol; 2010 Feb; 63(2):169-73. PubMed ID: 20154039
[TBL] [Abstract][Full Text] [Related]
14. Tumor markers CA 125, carcinoembryonic antigen and tumor-associated trypsin inhibitor in patients with cervical adenocarcinoma.
Leminen A
Gynecol Oncol; 1990 Dec; 39(3):358-63. PubMed ID: 2258083
[TBL] [Abstract][Full Text] [Related]
15. A comparison of the usefulness of serum measurements of CA 125, CA 50 and TATI in patients with malignant and benign gynecological pathology.
Gadducci A; Ferdeghini M; Facchini V; Ceccarini T; Prontera C; Bianchi R; Fioretti P
Eur J Gynaecol Oncol; 1990; 11(2):111-5. PubMed ID: 2379509
[TBL] [Abstract][Full Text] [Related]
16. A comparative evaluation of the ability of serum CA 125, CA 19-9, CA 15-3, CA 50, CA 72-4 and TATI assays in reflecting the course of disease in patients with ovarian carcinoma.
Gadducci A; Ferdeghini M; Ceccarini T; Prontera C; Facchini V; Bianchi R; Fioretti P
Eur J Gynaecol Oncol; 1990; 11(2):127-33. PubMed ID: 2379512
[TBL] [Abstract][Full Text] [Related]
17. Pre-operative serum level of tumour-associated trypsin inhibitor and residual tumour size as prognostic indicators in Stage III epithelial ovarian cancer.
Venesmaa P; Stenman UH; Forss M; Leminen A; Lehtovirta P; Vartiainen J; Paavonen J
Br J Obstet Gynaecol; 1998 May; 105(5):508-11. PubMed ID: 9637119
[TBL] [Abstract][Full Text] [Related]
18. Tumour-associated trypsin inhibitor and tumour-associated trypsin.
Stenman UH
Scand J Clin Lab Invest Suppl; 1990; 201():93-101. PubMed ID: 2244188
[TBL] [Abstract][Full Text] [Related]
19. Expression of trypsinogen-1, trypsinogen-2, and tumor-associated trypsin inhibitor in ovarian cancer: prognostic study on tissue and serum.
Paju A; Vartiainen J; Haglund C; Itkonen O; von Boguslawski K; Leminen A; Wahlström T; Stenman UH
Clin Cancer Res; 2004 Jul; 10(14):4761-8. PubMed ID: 15269150
[TBL] [Abstract][Full Text] [Related]
20. Markers supplementing CA 125 in ovarian cancer.
Stenman UH; Alfthan H; Vartiainen J; Lehtovirta P
Ann Med; 1995 Feb; 27(1):115-20. PubMed ID: 7741989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
